On September 29, 2025, Wanbangde Biotech announced that its independently developed MCR cyclic peptide has shown superior weight-loss and metabolic regulation effects compared to existing GLP-1 drugs in preclinical studies.

By activating the melanocortin-4 receptor (MC4R), the cyclic peptide achieves multiple effects: suppressing appetite, regulating blood sugar and blood lipids, and preserving muscle mass.

In an 8-week animal trial, the high-dose group achieved a 1.25x greater weight reduction than the GLP-1 group, with no significant muscle loss. The company plans to launch Phase I clinical trials in Q2 2026.